Promising Initial Dose-Escalation Results from Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors announced November 16, 2022
Promising SRF388 Monotherapy Data in NSCLC announced, Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort November 16, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Ph 2 trial in advanced ER-positive breast cancer November 4, 2022
Capivasertib plus Faslodex significantly improved PFS vs. Faslodex in CAPItello-291 Ph 3 trial November 4, 2022
Initial Dose-Escalation Results from the First-in-Human Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors November 4, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC Presented November 4, 2022
FAILED TRIAL: Ph 2 AMEERA-3 trial of amcenestrant in ER+/HER2- advanced or metastatic breast cancer did not meet primary endpoint of improving PFS November 4, 2022
Preliminary Ph 1 Clinical Data from ARROS-1 Trial of NVL-520 for Patients with ROS1-Positive NSCLC reported November 4, 2022
Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer presented November 2, 2022
Data from CheckMate -76K Shows that Opdivo Reduced the Risk of Recurrence or Death by 58% vs. Placebo in Patients with Completely Resected Stage IIB/C Melanoma October 26, 2022
Positive Topline Results Announced from Final PFS Analysis of BRUKINSA vs IMBRUVICA in Ph 3 ALPINE trial in CLL patients October 19, 2022
TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With metastatic CRPC With BRCA Or ATM Mutations October 12, 2022
Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI October 12, 2022
PERLA Ph 2 trial Of Jemperli (Dostarlimab) + Chemotherapy In Patients With mNSCLC met the primary endpoint of ORR October 12, 2022
Results Of IDMC Review Of 12 Week Safety Data From ENVASARC Ph 2 Pivotal Trial announced – Trial To Proceed As Planned October 12, 2022
New Long-Term Data from L-MIND Shows Durable Response to Monjuvi® (tafasitamab-cxix) for R/R DLBCL Patients October 5, 2022
CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective in First Trial in Patients with Resistant Multiple Myeloma October 5, 2022
Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Responses in Ovarian Cancer and Mesothelioma October 5, 2022
Long-Term Data from Omidubicel Ph 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers October 5, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
Results from Ph 2 trial of zevorcabtagene autoleucel Ph 1b/2 study in RRMM patients announced September 28, 2022
Recommended Dose for Planned Registrational Study of NBTXR3 Plus Anti-PD-1 for Patients With mSCCHN Resistant to Prior Immunotherapy Established September 28, 2022
